Clinical Trial Update: Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating PT003 for cardiovascular hemodynamics in moderate to severe COPD was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT003

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: COPD | Phase 3 | Status: TERMINATED | Results posted: 2019-08-28